



RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

Elenco Short Communications

ID	N.pgm	Title	Presenting Author
20/06/2024 12.15 - 13.15 Novel insights in the management of chronic viral hepatitis			
432	SC 1	Experience from a single centre on HBV seroconversion in people living with HIV and HBV: the relevance of individual clinical history	Mattia Simion, Modena
235	SC 2	Safety and effectiveness of switching PWH with occult HBV infection to tenofovir-sparing regimens	Vincenzo Malagnino, Roma
466	SC 3	Occult HBV infection and archived resistance to 3TC could predict virological failure during 3TC/DTG maintenance antiretroviral therapy: a retrospective study	Tommaso Matucci, Pisa
423	SC 4	Risk of Hepatitis B reactivation in people with HIV (PWH) with isolated anti-core antibody (HBcAb) after switch to 2DR strategies with lamivudine(3TC)/dolutegravir (DTG)	Pierluigi Francesco Salvo, Roma
232	SC 5	HDV persistence is sustained by HBsAg mainly derived from integrated HBV-DNA and is independent from the extent of HBV reservoir	Stefano D'Anna, Roma
181	SC 6	Heterogeneity in the diagnostic sensitivities of HDV RNA quantification assays used in clinical practice in Italy: data from the first national quality control multicenter study	Romina Salpini, Roma
20/06/2024 13.15 - 14.15 Sexual health and love's labours			
359	SC 7	A hidden challenge: STIs detection prevalence during nPEP follow up. A retrospective analysis	Nicholas Brian Bana, Milano
212	SC 8	Increasing Gonorrhoea and Chlamydia infections observed in MSM in the early 2024	Christof Stingone, Roma
271	SC 9	Sexually transmitted infections in men-who-have-sex-with-men with HIV resistant to tenofovir/emtricitabine and/or cabotegravir	Tommaso Clemente, Milano
124	SC 10	Applying IANS consensus guidelines for anal cancer screening to men who have sex with men living with HIV: a focus on the HRA referral rate	Maria Gabriella Donà, Roma
42	SC 11	Inadequate compliance with STIs vaccinations among individuals attending a sexually transmitted infection clinic	Gabriele Cavazza, Milano
313	SC 12	Doxycycline post-exposure prophylaxis (DoxyPEP) real-life effectiveness in a cohort of men who have sex with men in Milan, Italy	Angelo Roberto Raccagni, Milano
20/06/2024 13.15 - 14.15 PrEParing for the future of prevention			
251	SC 13	Impact of PrEP cost on prophylaxis initiation in an Italian centre	Serena Venturrelli, Bergamo
182	SC 14	5 years activity of the Bergamo Fast Track City network: from 2019 looking toward the future	Ilaria Mercurio, Chiuduno BG
5	SC 15	How the perception of PrEP has changed in the PrEP Point Plus (PPP) user group	Sandro Mattioli, Bologna
345	SC 16	Factors associated with PrEP start after nPEP conclusion. A retrospective analysis	Nicholas Brian Bana, Milano
154	SC 17	Interest for long-acting PrEP use in the Italian LGBTQIA+ community: a multicentric survey	Marco Stizioli, Montichiari BS
394	SC 18	What about a change? A survey in PrEP users about interest in injectable Long-Acting agents	Alessandra Bianchi, Milano



RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

Elenco Short Communications

ID	N.pgm	Title	Presenting Author
20/06/2024 13.15 - 14.15 HIV associated comorbidities: interplaying matters			
27	SC 19	Lipids, weight gain and Body Mass Index in ARV experienced PLWH treated with Doravirine-based treatments: a comparison between dual or triple regimens vs Bicitgravir based triple regimen	Addolorata Masiello, Caserta
127	SC 20	Dyslipidemia and real-life prescription of statins among People Living With HIV enrolled in Archi Prevaleat cohort	Benedetto Maurizio Celesia, Catania
28	SC 21	The dangerous liaisons: Correlation between lipid profile, subclinical atherosclerosis, hepatic steatosis and hepatic fibrosis in PLWH	Alessandra Tartaglia, Foggia
96	SC 22	A 48-week randomized controlled study of a home-based, app-monitored physical exercise intervention for older people with sarcopenia (Grow Your Muscle - GYM study): Preliminary results on muscle function and body composition at Week-12	Federica Marmondi, Milano
9	SC 23	Changes in bone mineral density in antiretroviral therapy-naive people living with HIV -1 aged over 50 years and starting bicitgravir/emtricitabine/tenofovir alafenamide	Maddalena Giglia, Bologna
354	SC 24	Evolution of anal HPV infection and HPV-related squamous intraepithelial lesions in a cohort of PLWH: is there a benefit of HPV vaccination?	Alessandra Bailoni, Siena
20/06/2024 15.25 - 16.25 Factors affecting treatment success: from pharmacology to drug resistance			
355	SC 25	The impact of pharmacogenetics on long-acting cabotegravir and rilpivirine plasma exposures in the clinical setting	Jessica Cusato, Torino
25	SC 26	The case of dolutegravir plus darunavir antiretroviral regimens: Is it always useful to double the drug doses?	Dario Cattaneo, Milano
167	SC 27	Comparative analysis of islatravir and tenofovir in vitro activity in NRTI resistant HIV-1 harboring the M184V/I mutation	Niccolò Bartolini, Siena
218	SC 28	Evaluation of HIV-1 drug resistance in newly diagnosed individuals in Italy according to subtype over the period 2017-2023	Francesco Bassani, Legnano MI
322	SC 29	Resistance detected in PBMCs predicts virological rebound in HIV-1 suppressed people with HIV-1 switching to modern antiretroviral regimens	Elio Gentilini Cacciola, Roma
63	SC 30	Ultra-deep sequencing of near full-length HIV-1 genomes for detecting natural resistance to lenacapavir and fostemsavir	Elisabetta Lazzari, Roma



RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

Elenco Short Communications

ID	N.pgm	Title	Presenting Author
20/06/2024 16.30 - 17.30 COVID-19 Unmasked: role of immunity and early treatment			
180	SC 31	SARS-CoV-2 vaccination influence in development of Long-COVID clinical phenotypes	Michele Antonacci, Roma
473	SC 32	A machine learning tool to operationalize Intrinsic Capacity in predicting recovery from post-acute sequelae COVID-19	Jovana Milic, Modena
267	SC 33	MicroRNAs in SARS-CoV-2 infection: a comparative analysis in immunocompromised versus non-immunocompromised patients	Chiara Siniscalchi, Napoli
275	SC 34	Impact of Early Antiviral Therapy on Time to SARS-CoV-2 Clearance in High-Risk COVID-19 Patients: A Propensity Score Matching Study	Marta Colaneri, Milano
294	SC 35	Efficacy and safety of Sotrovimab vs oral antivirals in Omicron waves: a retrospective analysis	Chiara Cacace, Napoli
222	SC 36	SARS-CoV-2-specific neutralizing activity and cytokine profile in newborns of vaccinated and/or infected and vaccinated mothers	Claudia Vanetti, Milano
21/06/2024 10.30 - 11.30 Hot topics in the epidemiology of relevant chronic and respiratory viral infections			
21	SC 37	HIV infection among migrants present in Italy from 2012 to 2022: incidence and characteristics	Vincenza Regine, Roma
191	SC 38	High rates of anal polyomaviruses and HPV co-infection among people living with HIV	Matteo Fracella, Roma
289	SC 39	Trends of toxoplasma antibody prevalence in naive people living with HIV in Italy. Data from the ICONA cohort	Giorgio Bozzi, Milano
120	SC 40	Epidemiological evolution of Hepatitis C Virus infection and treatment outcomes in Tuscany (Italy): a comprehensive analysis spanning the direct-acting antiviral era and the impact of the COVID-19 pandemic	Maria Paola Tramonti Fantozzi, Pisa
108	SC 41	Cases of untyped Influenza A virus in northern Italy	Irene Giberti, Genova
336	SC 42	Respiratory syncytial virus viral load and co-infection in a very large cohort of pediatric patients, which role in the disease severity?	Rossana Scutari, Roma
21/06/2024 13.00 - 13.50 Bridging innate and adaptive immunity in viral infections			
362	SC 43	Modulation of Cytomegalovirus (CMV) T cells response in PLWH after switching to long-acting (LA) cabotegravir plus rilpivirine	Mariasilvia Guardiani, Roma
356	SC 44	T cells profile in persons living with HIV (PLWH) with Progressive Multifocal Leucoencefalopathy (PML)	Eleonora Cimini, Roma
332	SC 45	Comparing T-Spot and In-House IGRA for Assessing SARS-CoV-2-Specific Cell-Mediated Immunity	Livia Benedetti, Roma
117	SC 46	Vδ2 T cells effector response in PLWH and PLWoH up to three months from mpox infection	Eleonora Cimini, Roma
132	SC 47	Are neutralizing autoantibodies to type I interferon novel disease determinants in people living with HIV?	Ginevra Bugani, Roma



RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

Elenco Short Communications

ID	N.pgm	Title	Presenting Author
21/06/2024	15.05 - 16.05	Stigma, awareness and education	
448	SC 48	Stigma on Screen: A Systematic Review of Cinema's HIV Narrative between 2016 and 2023	Agnese Colpani, Sassari
197	SC 49	Minority stress and stigmatizing attitudes towards HIV: a cross-sectional study among MSM on PrEP, people living with HIV and people not living with HIV in Italy	Filippo Maria Nimbi, Bologna
72	SC 50	Experience of a community-based chemsex service: analysis of requests for help during the MDPV outbreak	Alessandra Bianchi, Milano
316	SC 51	Chemsex knowledge and use among PrEP-users and PWH: a survey on the Milanese scene	Chiara Fusetti, Milano
308	SC 52	Comprehensive sexual health education in Italian secondary schools: preliminary results of the EduForIST national project	Alice Chinelli, Pisa
325	SC 53	From information to test: the experience with high school students	Caterina Pellegris, Chioduno BG